Abstract
Inhaled recombinant Secretory Leukocyte Protease Inhibitor (rSLPI) has shown potential for treatment of inflammatory lung conditions. Rapid inactivation of rSLPI by cathepsin L (Cat L) and rapid clearance from the lungs have limited clinical efficacy. Encapsulation of rSLPI within 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine]:Cholesterol liposomes (DOPS-rSLPI) protects rSLPI against Cat L inactivation in vitro. We aimed to determine the effect of liposomes on rSLPI pharmacokinetics and activity in vitro and after local delivery to the airways in vivo.
Original language | English |
---|---|
Pages (from-to) | 2233-2245 |
Number of pages | 13 |
Journal | Pharmaceutical Research |
Volume | 28 (9) |
Issue number | 9 |
DOIs | |
Publication status | Published - Sep 2011 |
ASJC Scopus subject areas
- Pharmaceutical Science
- Organic Chemistry
- Molecular Medicine
- Pharmacology (medical)
- Biotechnology
- Pharmacology